Second-line and subsequent therapy for ovarian carcinoma

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Cancer Research

Background:

• Ovarian carcinoma is the leading cause of death among gynecologic malignancies.
• Current standard treatment involves paclitaxel and platinum chemotherapy post-surgery.
• Salvage chemotherapy for relapsed disease shows limited efficacy.

Purpose of the Study:

• To review current treatment strategies for ovarian cancer.
• To explore promising novel therapeutic approaches.
• To emphasize the importance of clinical trials for advanced ovarian cancer.

Main Methods:

• Literature review of existing and emerging ovarian cancer treatments.
• Analysis of the efficacy of current chemotherapy regimens.
• Discussion of investigational therapies including immunotherapy, gene therapy, and targeted therapy.

Main Results:

• Standard chemotherapy has modest activity in relapsed ovarian cancer.
• Immunotherapy and gene therapy show promise for new ovarian cancer treatments.
• High-dose chemotherapy with stem-cell transplantation may benefit selected patients.

Conclusions:

• Development of new combination chemotherapy and targeted therapies is needed.
• Further investigation of whole abdominal radiotherapy for microscopic disease is warranted.
• Patient participation in clinical trials is essential for advancing ovarian cancer care.